{"podcast":{"title":"Business Of Biotech","slug":"business-of-biotech-123501","podcast_index_feed_id":123501,"rss_url":"https://rss.buzzsprout.com/1011661.rss","website_url":"https://www.bioprocessonline.com/solution/the-business-of-biotech-podcast","image_url":"https://storage.buzzsprout.com/35u0bccu9j9xpr9zrrjias54otax?.jpg","author":"Ben Comer","episode_count":310,"summary":"The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.","last_synced_at":"2026-06-08T22:18:30.179389+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501"},"episode":{"title":"Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane","slug":"rare-disease-drug-commercialization-with-zevra-therapeutics-neil-mcfarlane","published_at":"2026-05-25T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/rare-disease-drug-commercialization-with-zevra-therapeutics-neil-mcfarlane","show_page_url":"https://stenobird.com/podcast/business-of-biotech-123501","url":"https://www.buzzsprout.com/1011661/episodes/19208446-rare-disease-drug-commercialization-with-zevra-therapeutics-neil-mcfarlane.mp3","audio_url":"https://www.buzzsprout.com/1011661/episodes/19208446-rare-disease-drug-commercialization-with-zevra-therapeutics-neil-mcfarlane.mp3","summary":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Neil McFarlane, CEO at Zevra Therapeutics, talks about transitioning to a focused rare disease company through acquisitions, and building out a commercial organization. Neil explains the importance of working with rare disease patient advocacy groups, using AI to analyze electronic health records and claims data to identify and diagnose patients with Niemann-Pick disease type C, and adap...","meta_description":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Neil McFarlane, CEO at Zevra Therapeutics, talks…","key_points":[],"chapters":[],"topics":[],"duration_seconds":3323,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/rare-disease-drug-commercialization-with-zevra-therapeutics-neil-mcfarlane/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/rare-disease-drug-commercialization-with-zevra-therapeutics-neil-mcfarlane.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}